Product Life Management
Therapeutic drugs take years to develop and gain regulatory approval, and often have less than 10 years of patent life remaining by the time they reach market. Some drugs can be made safer and more efficacious by developing a breath-detectible SMART version that reports on patient adherence, or by incorporating future SMART capabilities such as reporting on blood concentration (therapeutic drug monitoring) or metabolic capacity. For opportunities such as these, pharmaceutical companies can enhance their brand investment by introducing a SMART version of the drug, which will derive additional patent protection from the underlying Xhale SMART patents.
The SMART version of the drug will have improved safety and efficacy (e.g., an Alzheimer's drug that reports to a family caregiver if the patient misses a scheduled dose of the drug, or an anti-depressant that confirms adolescent patients did not skip a dose), and as a result of the underlying Xhale patents the SMART drug version will enjoy additional market exclusivity.
Xhale has developed initial SMART designs for leading drugs in many therapeutic categories (including asthma, epilepsy, psychosis, depression, pain, coagulation, cancer and Alzheimer’s disease) where a leading drug on the market has limited remaining patent life, yet could be made more efficacious via a SMART version.